Skip to main content

Table 4 Differences in use of chemotherapy and endocrine therapy (ET) among the St Gallen risk categories.

From: Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer

 

Low

Intermediate

High

Chemotherapy without ET

349

12,429

8,007

ET without chemotherapy

4,019

9,629

671

Chemotherapy + ET

349

6,479

3,009

None or Unknown

4,407

15,697

2,653

Total

9,124

44,234

14,340

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us